This guide covers the clinical side effects of CBD, product safety failures across formats, health risks for vulnerable populations, regulatory and legal exposure, financial barriers, and the compliance tools available to CBD businesses.
CBD’s side effects range from mild first-use symptoms such as fatigue and nausea to clinically significant concerns including liver enzyme elevation and dangerous drug interactions, particularly with blood thinners and antidepressants.
Product safety failures are widespread. Studies show that fewer than one in four topical CBD products are accurately labeled, THC appears in 35% of tested topicals including those marked “THC free,” and vape products are the most severely mislabeled format in the category.
Vulnerable populations face compounded risks. Pregnant women, children, the elderly, and people with liver conditions each carry distinct physiological exposures that standard adult risk profiles underestimate, with the FDA specifically warning of liver injury and reproductive harm.
Regulatory and legal risk flows from overlapping federal authority. The 2018 Farm Bill legalized hemp but preserved FDA jurisdiction, leaving businesses exposed to enforcement gaps on labeling, health claims, and interstate commerce.
Financial operations add another layer of risk. Banks reject CBD merchants due to proximity to federally illegal substances, chargebacks threaten account stability above the 1% card network threshold, and high-risk processors charge fees between 3.49% and 3.95% with mandatory rolling reserves.
What Is CBD and Why Does It Carry Industry-Wide Risk?
CBD is cannabidiol, a non-intoxicating compound derived from the Cannabis sativa plant, and it carries industry-wide risk because it exists in a regulatory gray zone where federal, state, and financial rules frequently conflict. The following sections cover how CBD is legally defined, what makes it high-risk for financial institutions, and how its product landscape creates compliance exposure.
How Is CBD Legally Defined Under Federal Law?
CBD is legally defined under federal law as a compound derived from hemp, which the 2018 Farm Bill classifies as Cannabis sativa L. containing no more than 0.3% delta-9 THC on a dry weight basis. That bill removed hemp from the Controlled Substances Act, but it did not remove CBD from FDA jurisdiction. According to the Congressional Research Service, the Farm Bill explicitly preserved the FDA’s authority to regulate CBD-containing products under the Federal Food, Drug, and Cosmetic Act. This dual-authority structure is what creates ongoing compliance uncertainty for businesses selling CBD products.Why Do Financial Institutions Classify CBD as High-Risk?
Financial institutions classify CBD as high-risk because hemp-derived CBD still operates in proximity to federally illegal substances, exposing banks to legal, reputational, and regulatory consequences. The Association of Certified Anti-Money Laundering Specialists notes that banks face regulatory audits simply for servicing cannabis-adjacent businesses. Even technically compliant Hemp and CBD merchants trigger the same risk flags as prohibited operators, making traditional banking relationships difficult to establish and maintain.What Makes CBD Products Uniquely Risky Compared to Other Industries?
CBD products are uniquely risky compared to other industries because they carry simultaneous health, legal, and financial exposures that are rare in combination. On the health side, the World Health Organization found that pure CBD shows no abuse potential, yet commercially available products frequently diverge from that purity standard through mislabeling and contamination. On the business side, shifting state laws, FDA enforcement authority, and payment processor restrictions create operational vulnerabilities that most mainstream industries never face. That convergence of consumer safety risk and commercial compliance risk is what distinguishes CBD from nearly every other high-risk merchant category.What Are the Most Common Side Effects of CBD?
The most common side effects of CBD span both mild everyday symptoms and clinically significant events. The H3 sections below cover side effects by user type: first-time users, long-term users, high-dose scenarios, and medication interactions.
What Side Effects Does CBD Cause in First-Time Users?
The side effects CBD causes in first-time users are generally mild and include diarrhea, nausea, headache, fatigue, and changes in appetite and weight, according to the National Center for Toxicological Research. These effects typically reflect the body adjusting to cannabidiol rather than signs of toxicity. Notably, the WHO Expert Committee on Drug Dependence found that pure CBD does not appear to have abuse potential or cause harm, which is reassuring for new users but does not eliminate the possibility of short-term discomfort during initial use.What Side Effects Does CBD Cause With Long-Term Use?
The side effects CBD causes with long-term use include persistent gastrointestinal symptoms such as diarrhea, along with elevated hepatic enzyme levels and potential changes in body weight. Clinical studies reported a hepatic enzyme increase in 11% of patients and somnolence in 8%, effects that become more clinically relevant when CBD is taken consistently over time. Long-term users should monitor liver function periodically, particularly at higher maintenance doses.What Side Effects Does CBD Cause at High Doses?
The side effects CBD causes at high doses include abnormalities in liver-related blood tests. According to Harvard Health Publishing, this hepatotoxic effect was a primary reason treatment was discontinued in some clinical trials for Epidiolex, the FDA-approved CBD prescription drug. Dose-dependent liver stress is one of the most serious safety signals associated with CBD, making dose management critical for both consumers and clinicians.What Side Effects Does CBD Cause When Combined With Medications?
The side effects CBD causes when combined with medications include dry mouth, reduced appetite, drowsiness, and elevated drug plasma levels due to enzyme inhibition. According to the Mayo Clinic, CBD can interact with other medications, including certain antidepressants. This risk is particularly significant because CBD inhibits cytochrome P450 enzymes responsible for metabolizing a broad range of commonly prescribed drugs, meaning even standard CBD doses can alter how other medications perform in the body.What Are the Safety Concerns Specific to CBD Products?
The safety concerns specific to CBD products span four key risk areas: unregulated manufacturing, inaccurate labeling, contaminated hemp sources, and synthetic additives. Each H3 below addresses one of these risk categories in detail.
What Safety Risks Come From Unregulated CBD Manufacturing?
The safety risks from unregulated CBD manufacturing include mislabeled potency, undisclosed ingredients, and products that fail to meet their advertised spectrum type. A 2022 Johns Hopkins Medicine study of 105 topical CBD products found that only 24% were accurately labeled for CBD content, with 58% containing more than advertised. Separately, analysis of 202 CBD products published in Frontiers in Pharmacology found that 26% did not meet the definition for the product type claimed on the packaging. Without mandatory federal manufacturing standards, consumers have no reliable assurance that any over-the-counter CBD product contains what it claims.What Safety Risks Come From Inaccurate CBD Labeling?
The safety risks from inaccurate CBD labeling include unintended exposure to levels of hemp-derived compounds that exceed legal thresholds. According to a National Institute of Justice study, inaccurately labeled hemp samples frequently show total THC concentrations above the legal 0.3% threshold, with some exceeding 1%. This matters because consumers selecting products for zero-intoxicant use may unknowingly ingest amounts capable of producing psychoactive effects or triggering a positive drug test. Inaccurate labeling is not a minor compliance gap; it represents a direct public safety failure.What Safety Risks Come From Contaminated Hemp Sources?
The safety risks from contaminated hemp sources include exposure to heavy metals, pesticides, and residual solvents present in finished CBD products. Testing of commercially available CBD products has identified contaminants such as lead, arsenic, hexane, and methanol. Hemp is a bioaccumulator, meaning it absorbs compounds from soil at elevated rates, making source quality critical. Although the Congressional Research Service notes the 2018 Farm Bill removed hemp from the Controlled Substances Act, it did not override FDA authority to regulate hemp-derived compounds, so federal contamination standards still apply. Without verified sourcing, the supply chain risk remains substantial.What Safety Risks Come From Synthetic CBD Additives?
The safety risks from synthetic CBD additives include unpredictable pharmacological effects and an absence of clinical safety data for compounds that mimic natural cannabidiol. Synthetic CBD analogs are not subject to the same production controls as plant-derived CBD, and they may behave differently in the body despite similar chemical structures. These additives are sometimes introduced to boost the apparent potency of low-grade hemp extract, leaving consumers unknowingly exposed to untested substances. A published JAMA Network Open finding that 35% of tested CBD topical products contained detectable hemp-derived compounds, including 11% labeled “THC free,” underscores how opaque CBD formulations can be. Third-party certificate of analysis documentation is the only reliable safeguard consumers and merchants have against undisclosed additives.What Are the Health Risks of CBD for Vulnerable Populations?
The health risks of CBD for vulnerable populations vary significantly by group, including pregnant and nursing women, children and adolescents, the elderly, and people with liver conditions. Each sub-group faces distinct physiological exposures that standard adult risk profiles do not capture.
What Are the CBD Health Risks for Pregnant or Nursing Women?
The CBD health risks for pregnant or nursing women include potential liver injury, reproductive harm, and developmental effects on the fetus. The FDA specifically warns that CBD may cause liver injury and carry reproductive and developmental risks for this group. Supporting that concern, a review published in Obstetrics & Gynecology Survey found prenatal exposure associated with preterm birth, low birth weight, small for gestational age infants, and neonatal intensive care unit admission. Animal research has also shown CBD exposure leads to changes in fetal development. Given these findings, pregnant and nursing women should avoid CBD products entirely until human safety data is conclusive.What Are the CBD Health Risks for Children and Adolescents?
The CBD health risks for children and adolescents center on neurological development, dosing accuracy, and product mislabeling. The developing brain is more sensitive to cannabinoid exposure than an adult brain. Most over-the-counter CBD products are not formulated, tested, or dosed for pediatric use. Unlabeled contaminants, inaccurate concentrations, and unverified health claims in consumer products make unsupervised use especially dangerous for this age group. Only Epidiolex, the FDA-approved prescription CBD drug, carries validated safety and dosing data for pediatric epilepsy patients.What Are the CBD Health Risks for the Elderly?
The CBD health risks for the elderly include increased drug interaction potential, falls risk from sedation, and liver metabolism changes. Older adults are more likely to take multiple prescription medications simultaneously, raising the probability of CBD inhibiting cytochrome P450 enzymes and altering how those drugs are processed. Drowsiness and reduced appetite, both documented CBD side effects, pose compounded risks in elderly populations already managing balance, nutrition, and weight. This makes medical supervision particularly important before any elderly patient introduces CBD.What Are the CBD Health Risks for People With Liver Conditions?
The CBD health risks for people with liver conditions are among the most documented across all vulnerable groups. High doses of CBD have been shown to cause abnormal liver enzyme levels, which was a primary reason treatment was stopped in some clinical studies involving Epidiolex. People with pre-existing liver disease face a significantly lower tolerance threshold for hepatotoxic compounds. Additionally, CBD products advertised online have been unlawfully promoted with unauthorized health claims, which can mislead patients with serious conditions into substituting CBD for proven treatments, compounding clinical risk.What Are the Regulatory and Legal Risks in the CBD Industry?
The regulatory and legal risks in the CBD industry stem from overlapping federal authority, inconsistent labeling standards, and fragmented state laws. The following sections cover how the FDA’s jurisdiction, labeling compliance gaps, and interstate commerce rules each create distinct legal exposure for CBD businesses.How Does the FDA’s Stance Create Legal Risk for CBD Businesses?
The FDA’s stance creates legal risk because the Agriculture Improvement Act of 2018 legalized hemp but explicitly preserved the FDA’s authority to regulate CBD as a drug, food additive, or dietary supplement. This means hemp-derived CBD businesses operate in a legal gap: their products are not federally illegal, yet selling CBD in food, beverages, or supplements without FDA approval remains an unauthorized act. The FDA Commissioner has stated that selling unapproved products with unsubstantiated therapeutic claims violates federal law and risks patient safety. For CBD businesses, this dual exposure, complying with USDA hemp rules while avoiding FDA enforcement action, creates ongoing and unpredictable legal liability.What Labeling Compliance Risks Do CBD Companies Face?
The labeling compliance risks CBD companies face include inaccurate potency claims, false product-type classifications, and unauthorized health claims. Federal regulations require labels to reflect actual CBD concentrations and avoid unapproved drug claims, but enforcement is inconsistent. Products claiming to be “THC free,” “full spectrum,” or “broad spectrum” carry specific definitional requirements. A failure to meet these standards can trigger FDA warning letters, product seizures, or retailer delistings. For businesses, inaccurate labels also expose them to consumer fraud claims and chargebacks, compounding legal risk with financial liability.What Are the Interstate Commerce Legal Risks for CBD Sellers?
The interstate commerce legal risks for CBD sellers arise from variations in state laws regarding hemp and CBD, which create significant compliance difficulties for businesses operating across multiple jurisdictions. According to Cannabis Science and Technology, while federal law permits hemp-derived CBD transport across state lines, individual states may prohibit inbound shipments, require separate state licensing, or impose stricter concentration limits. A shipment legal at origin can become non-compliant upon arrival. Businesses shipping without verifying destination-state law risk product seizure, fines, and loss of merchant account status. Proactive legal review of each target state’s hemp statutes is, in practice, a non-negotiable cost of operating nationally.What Are the Financial and Operational Risks of Running a CBD Business?
The financial and operational risks of running a CBD business span banking access, fraud exposure, and multi-state legal compliance. The following sections cover why banks reject CBD merchants, what chargeback risks they face, and how inconsistent state laws create operational barriers.Why Do Banks and Payment Processors Reject CBD Businesses?
Banks and payment processors reject CBD businesses primarily because regulatory audits target financial institutions that serve the broader hemp and CBD industry. According to the Bank Administration Institute, banks providing services to these businesses become frequent subjects of regulatory scrutiny, making traditional banking products difficult to obtain. This creates a cascading operational problem: without stable banking relationships, CBD merchants struggle to manage payroll, vendor payments, and basic cash flow. In practice, this forces many businesses toward specialized high-risk processors as their only viable path to financial services.What Fraud and Chargeback Risks Do CBD Merchants Face?
The fraud and chargeback risks CBD merchants face include “friendly fraud” and elevated dispute rates that can trigger account freezes or terminations. Card networks enforce a chargeback threshold of 1%, and exceeding it puts a merchant’s processing account at immediate risk. Because CBD purchases are sometimes disputed after delivery, merchants are particularly vulnerable to this type of fraudulent reversal. Proactive chargeback management, including clear billing descriptors and robust refund policies, is one of the most underestimated operational requirements in this industry.What Business Risks Come From Inconsistent State CBD Laws?
The business risks from inconsistent state CBD laws include significant interstate commerce exposure and compliance failures for businesses selling across multiple jurisdictions. According to Cannabis Science and Technology, variations in state-level hemp and CBD regulations create compounding legal difficulties when products cross state lines. A product legally sold in one state may be restricted or outright prohibited in another, making multi-state operations inherently complex. CBD businesses expanding nationally must treat each state as a distinct compliance environment rather than assuming federal hemp legality provides uniform protection.What Product-Specific Risks Exist Across Different CBD Formats?
Product-specific risks vary by CBD format, covering concerns related to dosing accuracy, labeling integrity, inhalation safety, skin absorption, and supplement standardization. The sections below examine the distinct safety profile of oils and tinctures, edibles, vape products, topicals, and capsules.What Are the Safety Risks of CBD Oils and Tinctures?
The safety risks of CBD oils and tinctures center on dosing inconsistency and carrier oil quality. Because tinctures are measured in drops, minor variations in dropper technique can produce significantly different doses. Oils using low-grade carrier bases may also introduce contaminants such as residual solvents or pesticides. Without third-party lab verification, consumers have no reliable way to confirm the CBD concentration or purity of what they are ingesting.What Are the Safety Risks of CBD Edibles and Gummies?
The safety risks of CBD edibles and gummies include unreliable dosing, delayed onset, and significant mislabeling. Edible CBD products may contain very little of the advertised CBD, with some studies showing an average Hemp and CBD ratio of 36-to-1 in certain samples. Because digestion delays absorption by 30 to 90 minutes, users often consume additional doses before the first takes effect, increasing the risk of unintended overconsumption and adverse reactions.What Are the Safety Risks of CBD Vape Products?
The safety risks of CBD vape products include lung irritation and severe mislabeling. According to a JAMA study, vape products were the most frequently mislabeled CBD format, with 87.5% of tested samples showing inaccurate CBD concentrations. The FDA has also raised concerns about unknown compounds introduced during the vaping process. Given how consistently inaccurate vape labeling has proven to be, this format carries a higher combined health and consumer protection risk than most other CBD delivery methods.What Are the Safety Risks of CBD Topicals and Creams?
The safety risks of CBD topicals and creams include unintended Hemp and CBD exposure and inaccurate product labeling. A study found that only 24% of topical CBD products were accurately labeled for CBD content, with 58% containing more than advertised. Topicals are generally considered lower risk than ingestible formats because systemic absorption through intact skin is minimal, though they still present labeling reliability concerns that affect consumer trust and compliance.What Are the Safety Risks of CBD Capsules and Supplements?
The safety risks of CBD capsules and supplements involve inconsistent standardization and unverified label claims. Capsules marketed as dietary supplements are not subject to the same pre-market approval standards as pharmaceuticals, meaning manufacturers are not required to prove potency or purity before selling. Without a verified Certificate of Analysis from an accredited independent lab, consumers cannot confirm whether the capsule contains the stated CBD dose or is free from heavy metals, pesticides, or residual solvents.What Are the Risks of Mislabeled or Low-Quality CBD Products?
Mislabeled and low-quality CBD products expose consumers to contamination, incorrect dosing, and unverified safety profiles. The H3s below cover Hemp and CBD contamination risk, third-party lab testing standards, and the dangers of purchasing without a Certificate of Analysis.How Does THC Contamination in CBD Products Create Risk?
THC contamination in CBD products creates risk by exposing users to psychoactive compounds they did not consent to and by triggering dangerous drug interactions. CBD-containing products can interfere with the pharmacokinetics of the blood thinner warfarin, increasing the International Normalized Ratio (INR) and raising bleeding risk, according to case reports published in the Journal of Clinical Medicine. Consumers who believe they are buying THC-free products may unknowingly compound these risks. The FDA Commissioner has stated that “Selling unapproved products with unsubstantiated therapeutic claims is not only a violation of the law, but also can put patients at risk,” underscoring that mislabeling is both a legal and public health failure.How Do Third-Party Lab Tests Reduce CBD Product Safety Risks?
Third-party lab tests reduce CBD product safety risks by independently verifying purity and potency before a product reaches consumers. According to Ellipse Analytics, third-party lab testing for CBD products typically screens for 232 pesticides, four heavy metals, and 15 residual solvents. This level of screening catches contaminants, such as lead, arsenic, hexane, and methanol, that internal manufacturer testing may miss or suppress. For consumers and regulators alike, third-party results provide the only objective benchmark for safety claims on a label. Relying solely on a brand’s self-reported data is one of the most underestimated risks in the CBD market.What Are the Risks of Buying CBD Without a Certificate of Analysis?
The risks of buying CBD without a Certificate of Analysis (COA) include receiving a product with unverified Hemp and CBD concentrations, undisclosed contaminants, and no legal accountability trail. A COA from an independent, accredited lab confirms that a product contains less than 0.3% Hemp and CBD-derived compounds and is free from harmful residuals. Without it, consumers have no way to verify whether labeling claims are accurate or whether the product meets minimum compliance standards. Certificate of Analysis requirements exist specifically to create a documented chain of evidence between the manufacturer and the end user, making a missing COA a significant red flag for both safety and regulatory compliance.How Can CBD Businesses Manage Risk and Stay Compliant?
CBD businesses manage risk and stay compliant through three core disciplines: building legal compliance practices, enforcing quality control standards, and protecting against chargebacks.What Compliance Practices Reduce Legal Risk for CBD Companies?
Compliance practices that reduce legal risk for CBD companies include maintaining accurate product labeling, avoiding unauthorized health claims, and tracking state-by-state regulatory requirements. The FDA Commissioner has stated that “Selling unapproved products with unsubstantiated therapeutic claims is not only a violation of the law, but also can put patients at risk.” CBD products have also been unlawfully marketed online with therapeutic claims that violate FDA guidelines. Practically speaking, CBD brands that invest in proactive compliance monitoring are far less likely to face enforcement actions, account terminations, or costly legal disputes.What Quality Control Standards Should CBD Brands Follow?
Quality control standards CBD brands should follow center on third-party lab testing and accurate product documentation. Certificate of Analysis (COA) requirements from independent, accredited laboratories are mandatory for CBD merchants to demonstrate their products contain less than 0.3% Hemp and CBD content and are free from contaminants. According to Ellipse Analytics, third-party lab testing for CBD products typically includes screening for 232 pesticides, four heavy metals, and 15 residual solvents. Brands that skip this step expose themselves to mislabeling liability, regulatory action, and consumer harm, making rigorous testing one of the highest-return investments a CBD company can make.How Can CBD Merchants Protect Themselves From Chargebacks?
CBD merchants can protect themselves from chargebacks by maintaining transparent billing practices, clear refund policies, and strong dispute documentation. CBD merchants face friendly fraud and elevated chargeback rates, and if ratios exceed the card network threshold of 1%, merchants risk account freezes or terminations. Proactive tools such as real-time fraud monitoring, clear product descriptions, and documented customer communication significantly reduce exposure. Understanding this risk and building systems around it early is far more effective than reacting after an account is already flagged.How Do High-Risk Payment Solutions Help CBD Businesses Manage Industry Risk?
High-risk payment solutions help CBD businesses manage industry risk by providing specialized infrastructure for compliance monitoring, fraud prevention, and chargeback management. The two H3s below cover processor capabilities and key article takeaways.